Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Terry A. McNearney"'
Autor:
Terry A. McNearney, Karin N. Westlund
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 17, p 13196 (2023)
The N-methyl-D-aspartate (NMDA) glutamate receptors function as plasma membrane ionic channels and take part in very tightly controlled cellular processes activating neurogenic and inflammatory pathways. In particular, the NR1 subunit (new terminolog
Externí odkaz:
https://doaj.org/article/5bca35e509914ff9a923809d93ce35af
Autor:
Karin N. Westlund, Ying Lu, Liping Zhang, Todd C. Pappas, Wen-Ru Zhang, Giulio Taglialatela, Sabrina L. McIlwrath, Terry A. McNearney
Publikováno v:
Frontiers in Physiology, Vol 11 (2020)
In the lumbar spinal cord dorsal horn, release of afferent nerve glutamate activates the neurons that relay information about injury pain. Here, we examined the effects of protein tyrosine kinase (PTK) inhibition on NMDA receptor NR1 subunit protein
Externí odkaz:
https://doaj.org/article/fbc1653fd82641d5b376bdd486f292ed
Autor:
Terry A. McNearney, Biai D.E. Digbeu, Dennis Ladnier, Kawther Abdilleh, Sudheer Doss, Lynn M. Matrisian, Jacques G. Baillargeon
Publikováno v:
Cancer Research. 82:A020-A020
Objective: This study assessed the pancreatic cancer (PC) patient-reported burdens of PC pain from 2016-2020 in an online patient-reported outcomes (PRO) survey supported by the Pancreatic Cancer Action Network (PanCAN). Assessments of PC symptoms, P
Autor:
Terry A. McNearney, Joyce Joseph, Hilda T. Draeger, Shervin Assassi, Sam Theodore, Maureen D. Mayes, Claudia Pedroza, John D. Reveille, Maryam Buni, Deepthi Nair
Publikováno v:
The Journal of Rheumatology. 46:1597-1604
Objective.To identify baseline features that predict progression of hand contractures and to assess the effect of contractures on functional status in the prospective GENISOS cohort.Methods.Rate of decline in hand extension, as an indicator of hand c
Autor:
Alan Kivitz, Y. Jin, Claire Smith, David Monteith, Eyas Raddad, R. Brown, Mark A. Deeg, Terry A. McNearney, A. Camporeale, N. Xiao, A. de la Peña, Thomas J. Schnitzer
Publikováno v:
Osteoarthritis and Cartilage. 26:1609-1618
Summary Objective This study tested whether galcanezumab, a humanized monoclonal antibody with efficacy against migraine, was superior to placebo for the treatment of mild or moderate osteoarthritis (OA) knee pain. Method In a multicenter, double-bli
Autor:
Leijun Hu, Jeanelle Kam, William H. Landschulz, Masako Nakano, Xiao Yan Yang, Arie Regev, Claire Smith, Jack Uetrecht, Terry A. McNearney, Y. Jin, D. Greg Hall, Kristina M. Campanale, Krista M Phipps, Judith W. Henck
Publikováno v:
British Journal of Clinical Pharmacology. 84:179-188
SummaryAim LY3031207, a novel microsomal prostaglandin E synthase 1 inhibitor, was evaluated in a multiple ascending dose study after nonclinical toxicology studies and a single ascending dose study demonstrated an acceptable toxicity, safety, and to
Autor:
Xiao Yang, Krista M Phipps, Thomas G. Pottanat, Leijun Hu, Claire Smith, Kelly Whitehurst, William H. Landschulz, Terry A. McNearney, Bradley L. Ackermann, David E. Coutant, Y. Jin
Publikováno v:
Clinical and Translational Science. 11:46-53
Safety, tolerability, and pharmacology profiles of LY3127760, an EP4 antagonist, were explored in healthy subjects in a subject/investigator-blind, parallel-group, multiple-ascending dose study. Cohorts consisted of 13 patients randomized to LY312776
Autor:
Claire Smith, Bradley L. Ackermann, Terry A. McNearney, Xiao Yan Yang, LG Huffman, R Stoltz, Leijun Hu, Arie Regev, R Dean, Y. Jin, William H. Landschulz, Kristina M. Campanale
Publikováno v:
Clinical Pharmacology & Therapeutics. 99:274-284
To assess the safety, tolerability, and pharmacology of LY3023703, a microsomal prostaglandin E synthase 1 (mPGES1) inhibitor, a multiple ascending dose study was conducted. Forty-eight subjects received LY3023703, celecoxib (400 mg), or placebo once
Autor:
Thomas J. Schnitzer, David Monteith, Terry A. McNearney, Roger Brown, Claire Smith, Y. Jin, Xiao Ni, Mark A. Deeg, Eyas Raddad
Publikováno v:
Pharmaceutical statistics. 18(1)
Development of new pharmacological treatments for osteoarthritis that address unmet medical needs in a competitive market place is challenging. Bayesian approaches to trial design offer advantages in defining treatment benefits by addressing clinical
Autor:
Terry A. McNearney, Alan Kivitz, R. Brown, Mark A. Deeg, Y. Jin, Claire Smith, Thomas J. Schnitzer, E.C. Collins, Jayne A. Talbot, A. Camporeale, D Montieth
Publikováno v:
Poster Presentations.
Background The safety and efficacy of galcanezumab, a monoclonal antibody directed against CGRP, were assessed in a phase 2 clinical trial NCT02192190 in patients with moderate to severe osteoarthritis (OA) knee pain. Patients were randomized to plac